Seagen : CHMP Confirms Positive Opinion For PADCEV In Metastatic Urothelial Cancer
28/2 14:54
(RTTNews) - Astellas Pharma and Seagen Inc. (SGEN) said Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its previously adopted positive opinion, recommending approval of PADCEV (enfortumab vedotin) as mono...